Okubo Toshiki, Iwanami Akio, Kohyama Jun, Itakura Go, Kawabata Soya, Nishiyama Yuichiro, Sugai Keiko, Ozaki Masahiro, Iida Tsuyoshi, Matsubayashi Kohei, Matsumoto Morio, Nakamura Masaya, Okano Hideyuki
Department of Orthopaedic Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; Department of Physiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Department of Orthopaedic Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Stem Cell Reports. 2016 Oct 11;7(4):649-663. doi: 10.1016/j.stemcr.2016.08.015. Epub 2016 Sep 22.
Neural stem/progenitor cells (NS/PCs) derived from human induced pluripotent stem cells (hiPSCs) are considered to be a promising cell source for cell-based interventions that target CNS disorders. We previously reported that transplanting certain hiPSC-NS/PCs in the spinal cord results in tumor-like overgrowth of hiPSC-NS/PCs and subsequent deterioration of motor function. Remnant immature cells should be removed or induced into more mature cell types to avoid adverse effects of hiPSC-NS/PC transplantation. Because Notch signaling plays a role in maintaining NS/PCs, we evaluated the effects of γ-secretase inhibitor (GSI) and found that pretreating hiPSC-NS/PCs with GSI promoted neuronal differentiation and maturation in vitro, and GSI pretreatment also reduced the overgrowth of transplanted hiPSC-NS/PCs and inhibited the deterioration of motor function in vivo. These results indicate that pretreatment with hiPSC-NS/PCs decreases the proliferative capacity of transplanted hiPSC-NS/PCs, triggers neuronal commitment, and improves the safety of hiPSC-based approaches in regenerative medicine.
Neural Regen Res. 2025-9-1
Spine Surg Relat Res. 2023-9-4
Circ Res. 2013-2-1
Biochem Biophys Res Commun. 2012-2-5
Proc Natl Acad Sci U S A. 2011-9-26